Oncogenesis News and Research

RSS

New strategies to enhance the survival of children with neuroblastoma

Neuroblastoma, a childhood cancer that develops from neural cells on the adrenal glands, accounts for 15% of childhood cancer deaths. Almost half of children with high-risk neuroblastoma harbor extra copies of the gene MYCN (MYCN amplified), the primary driver of neuroblastoma and its resistance to therapy.

18 Aug 2022

Researchers determine optimal conditions to perform impedance cytometry

Having a good eye for detail is an essential skill for many professions. In particular, biologists use special techniques and advanced technology to analyze individual cells with unprecedented precision.

24 Jun 2022

New technique can accurately detect viruses in tumors from clinical next-generation sequencing

Researchers have developed a method to accurately detect viruses from clinical next-generation sequencing and describe novel associations between specific tumors and viruses that warrant further investigation.

5 May 2022

New data-driven mechanistic approach can help reduce drug costs and treat diseases

A new data-driven mechanistic approach that predicts cell types within tissue will help to reduce drug costs and treat diseases that were difficult to develop drugs for, according to a West Virginia University scientist.

14 Apr 2022

Researchers find novel inhibitors that may suppress oncogenesis of metastatic prostate cancer

Researchers have found that treating prostate cancer cells with novel cyclin-dependent kinase 19 (CDK19) and homologous cyclin-dependent kinase 8 (CDK8) inhibitors reduces their potential to migrate into and invade surrounding structures.

13 Apr 2022

Scientists uncover new role of chromatin-modulatory enzyme during cancer development

Researchers at the University of North Carolina at Chapel Hill and the UNC Lineberger Comprehensive Cancer Center have uncovered a new role of a chromatin-modulatory enzyme, termed EZH2, during cancer development.

24 Feb 2022

Researchers identify and characterize a previously unrecognized key player in cancer evolution

Researchers led by bioengineers at the University of California San Diego have identified and characterized a previously unrecognized key player in cancer evolution: clusters of mutations occurring at certain regions of the genome.

9 Feb 2022

Potential tumor vulnerability may be exploited to improve treatment of neuroblastoma

A Ludwig Cancer Research study has identified a potential vulnerability in neuroblastoma tumors that might be exploited to improve treatment of the aggressive childhood cancer, which accounts for roughly 15% of all deaths from pediatric malignancies.

7 Feb 2022

Study identifies a genetic mutation linked to high risk of lethal childhood leukemia

A genetic variant changing just one base pair of nucleotides greatly increases risk of a high-risk subtype of childhood acute lymphoblastic leukemia (ALL), according to a Northwestern Medicine study published in Nature Genetics.

3 Feb 2022

Virus-like particles as delivery vehicles for gene-editing

Scientists deliver gene-editing proteins through the use of engineered virus-like particles, which mediated efficient base editing both in vitro and in vivo.

13 Jan 2022

LJI researchers discover how loss of TET enzymes can lead to B cell lymphoma

Scientists at the La Jolla Institute for Immunology have uncovered how loss of TET enzymes can lead to B cell lymphoma. Their research, published in Nature Immunology, could potentially open opportunities for designing drug treatment strategies to target malignant cells in many cancers.

24 Dec 2021

Study reveals chromosome-level changes that relate to drug resistance in melanoma

Precision therapies targeting melanoma and other cancers have improved patient survival, but tumors often stop responding to drugs, and recent studies point to changes in DNA – both inside and outside chromosomes – as a driving factor in tumor genesis as well as in treatment resistance.

20 Dec 2021

Penn Medicine and Wistar secure $11.7 million SPORE grant for three melanoma research projects

Penn Medicine and The Wistar Institute have been awarded a prestigious $11.7 million Specialized Programs of Research Excellence, or SPORE, grant from the National Cancer Institute.

22 Sep 2021

Study finds 24% higher prostate cancer risk among rescue/recovery workers after World Trade Center attacks

The risk of prostate cancer was 24% higher among 9/11 rescue and recovery workers after the attacks on the World Trade Center in 2001, with the highest risk among the earliest responders, finds research published online in the journal Occupational & Environmental Medicine.

13 Sep 2021

UAB researchers identify potential therapeutic target for ovarian cancer

A gene called DOT1L appears to play a role in progression and severity of ovarian cancer, and inhibitors of the DOT1L enzyme may offer a new therapeutic approach for the disease, University of Alabama at Birmingham researchers say in a study published in the journal Oncogenesis.

5 Aug 2021

Two CU Cancer Center studies provide insights into the link between inflammation and leukemia

Two recent collaborative publications by CU Cancer Center members provide insights into how chronic inflammation can serve as a key factor in the development of leukemia and other blood cancers.

29 Jun 2021

Mutation-signature–associated metrics predict cancer progression in patients

Oncotarget published "Predicting clinical outcomes using cancer progression associated signatures" which reported somatic mutation signatures are an informative facet of cancer etiology, however they are rarely useful for predicting patient outcome.

28 Jun 2021

Nanopore sequencing contradicts human genome integration of SARS-CoV-2

Now a new preprint research paper posted to the bioRxiv* server dismisses the possibility, raised by that study, that the virus inserts its genetic material into the host cell’s genome.

2 Jun 2021

Molecular subtype of cancer preferentially affects people with Indigenous ancestry

Oncotarget published "Global DNA hypermethylation pattern and unique gene expression signature in liver cancer from patients with Indigenous American ancestry" which reported that contrasting with this pattern, the age structure of HCC in Andean people displays a bimodal distribution with half of the patients developing HCC in adolescence and early adulthood.